Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
Timothy Price(Queen Elizabeth Hospital), Marc Peeters(University of Antwerp), Tae Won Kim(University of Ulsan), Jin Li(Fudan University Shanghai Cancer Center), Stefano Cascinu(Marche Polytechnic University), Paul Ruff(University of the Witwatersrand), Atilli Satya Suresh(Apollo Hospitals), Anne Thomas(Leicester Royal Infirmary), Sergei Tjulandin(Russian Cancer Research Center NN Blokhin), Kathy Zhang(Amgen (United States)), Swaminathan Murugappan(Amgen (United States)), Roger Sidhu(Amgen (United States))
Cited by 468Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis